Arvinas price target lowered to $65 from $100 at Truist

Truist analyst Joon Lee lowered the firm’s price target on Arvinas (ARVN) to $65 from $100 but keeps a Buy rating on the shares. The release of drug-drug interactions, or DDI, between ARV-471 and palbo disclosed by the company along with Pfizer (PFE) last week complicates clinical development of ARV-471, but it is also common and he is confident that the companies will be able to chart a viable clinical path forward, the analyst tells investors in a research note. Reducing palbo. which is available in lower dosages, could be an easy fix, Lee adds.